Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: Initial clinical observations revealed strikingly longer follow-up for metastatic non-small-cell lung cancer (NSCLC) patients receiving nivolumab infusions predominantly in the morning as compared to those treated in the afternoon. Prior experimental and human studies have demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Karaboué, Abdoulaye, Collon, Thierry, Pavese, Ida, Bodiguel, Viviane, Cucherousset, Joel, Zakine, Elda, Innominato, Pasquale F., Bouchahda, Mohamed, Adam, René, Lévi, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870559/
https://www.ncbi.nlm.nih.gov/pubmed/35205644
http://dx.doi.org/10.3390/cancers14040896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870559/
https://www.ncbi.nlm.nih.gov/pubmed/35205644
http://dx.doi.org/10.3390/cancers14040896

Ejemplares similares